Building on the success of previous projects, the two parties aim to jointly explore high-value market opportunities.

Learn MoreBioGeometry and Sino Biological Deepen Strategic Cooperation to Empower Protein R&D with GenAI

Driving the transformation towards a digital, intelligent and sustainable future

Learn MoreBioGeometry secures Pre-A round funding to advance GenAI for biosolutions

Antibody-antigen docking performance on par with AlphaFold3

Learn MoreIntroducing GeoFlow: Next-Gen Generative Model for Antibody Modeling and Design

Both parties will create a next-generation AIGC-driven antibody drug discovery platform jointly and promote tripartite cooperation with significant innovative drug companies or biotech firms to enhance the efficiency of new drug R&D and help pharmaceutical R&D enterprises improve their global competitiveness.

Learn MoreBioGeometry Joins Hands with Sanyou to Build a New Generation AIGC-Driven Antibody Drug Discovery Platform

Both parties will fully leverage their respective strengths in a comprehensive strategic collaboration within the field of large molecule pharmaceuticals, aiming to achieve breakthrough progress in antibody drug R&D through the application of AI technology.

Learn MoreBioGeometry Announces Strategic Cooperation with Symray Biopharma for the Large Molecule Drug R&D

The two parties will engage in deep collaboration on platform products, project optimization services, and resource expansion to promote innovation together in antibody research and development, providing pharmaceutical clients with higher-quality R&D services.

Learn MoreBioGeometry and BioMetas Join Hands to Empower Development of Novel Large Molecule Drugs